Akonni and Righton Form Two-Way US-China Diagnostics Deal

Akonni Biosystems of Maryland and Righton, a China in vitro diagnostics company, announced a two-way commercial agreement. In China , Righton will sell Akonni's nucleic acid purification and molecular diagnostic products to researchers, clinical laboratories and hospitals, while Akonni will acquire exclusive marketing rights to Righton's 28 molecular diagnostic products outside of China . As part of the agreement, Righton made a $7.5 million investment in Akonni's series D round, bringing the funding to $13.9 million . More details.... Share this with colleagues: // //